trending Market Intelligence /marketintelligence/en/news-insights/trending/afC9EAuv-80uFEVrvhr7lw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

AstraZeneca's lung cancer treatment Imfinzi granted priority review by FDA

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


AstraZeneca's lung cancer treatment Imfinzi granted priority review by FDA

AstraZeneca PLC and MedImmune's Imfinzi was granted priority review status by the U.S. Food and Drug Administration as it accepted a supplemental biologics license application, or sBLA, for the lung cancer treatment.

The sBLA is based on positive data from the phase 3 Pacific trial of Imfinzi. The study is continuing to evaluate overall survival under the treatment, the trial's other primary endpoint.

Imfinzi or durvalumab, is a monoclonal antibody indicated for treating patients with locally advanced, or Stage 3, unresectable non-small cell lung cancer whose disease has not progressed following platinum-based chemoradiation therapy.

Imfinzi was granted breakthrough therapy designation by the U.S. FDA in July.

MedImmune is AstraZeneca's biologics research and development unit.